Empowering the Next Generation of Nephrologists: Trainee Opportunities in #GlomCon Ecosystem from @asnpublications.bsky.social @glomcon.org @bettercallseeth.bsky.social @saynanorouzi.bsky.social @nephrologista.bsky.social @poyanmehr.org
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41105470/
#Nephpearls #NephSky
👉 pubmed.ncbi.nlm.nih.gov/41105470/
October 18, 2025 at 3:09 PM
Everybody can reply
3 reposts
10 likes
Did you miss #GlomCon Hawaii? Don't worry, I took the hit and flew to Hawaii for a week so I could give all of you a summary of what went down. Read all about it...
DON'T MISS Joel Topf's reflections on #GlomConHawaii (plus a few gorgeous photos!). www.docwirenews.com/post/glomcon... @kidneyboy.bsky.social #nephrology #nephsky #glomerulardisease #kidneydisease
GlomCon Hawaii Conference Highlights | Docwire News
Nephrology Times editorial board member Joel Topf, MD, gives his perspective on GlomCon Hawaii 2025, a conference on glomerular diseases.
www.docwirenews.com
October 16, 2025 at 3:34 PM
Everybody can reply
3 reposts
5 likes
1 saves
DON'T MISS Joel Topf's reflections on #GlomConHawaii (plus a few gorgeous photos!). www.docwirenews.com/post/glomcon... @kidneyboy.bsky.social #nephrology #nephsky #glomerulardisease #kidneydisease
GlomCon Hawaii Conference Highlights | Docwire News
Nephrology Times editorial board member Joel Topf, MD, gives his perspective on GlomCon Hawaii 2025, a conference on glomerular diseases.
www.docwirenews.com
October 16, 2025 at 2:13 PM
Everybody can reply
2 reposts
1 quotes
3 likes
2 saves
Collaboration, innovation, education emerged as central themes at the 2nd GlomCon Hawaii conference. #glomerulardisease #kidneydisease #nephrology #nephsky #GlomConHawaii @glomcon.org www.docwirenews.com/post/innovat...
Innovation and Connection Define the Future of Glomerular Disease Treatment | Docwire News
Collaboration, innovation, and education emerged as central themes at the second annual GlomCon Hawaii conference, focused on glomerular diseases, including IgA nephropathy (IgAN).
www.docwirenews.com
October 15, 2025 at 4:05 PM
Everybody can reply
𝗧𝗢𝗗𝗔𝗬: Join GlomCon and the International Society of Nephrology (ISN) at 8:00 a.m. Pacific Time for an insightful session on
🧫 Glomerulopathy Associated with Parasitic Infections
with Dr. Ahmed Kalebi.
🆔 Zoom ID: 817 4374 4653
🔑 Passcode: 202122
📝 Sign up: http://bit.ly/signup...
🧫 Glomerulopathy Associated with Parasitic Infections
with Dr. Ahmed Kalebi.
🆔 Zoom ID: 817 4374 4653
🔑 Passcode: 202122
📝 Sign up: http://bit.ly/signup...
October 12, 2025 at 1:00 PM
Everybody can reply
1 reposts
2 likes
From Richard Lafayette at GlomCon
October 6, 2025 at 8:10 PM
Everybody can reply
2 reposts
5 likes
So grateful for the opportunity to share our experience with C3 glomerulopathy and complement-mediated thrombotic microangiopathy at the GlomCon Annual Conference in Hawaii, USA. Amazing learning, great networking, and the joy of finally meeting virtual friends in real life!
October 5, 2025 at 3:32 AM
Everybody can reply
Huge thank you to our incredible faculty, attendees, sponsors, and GlomCon instructors for making #GlomConHawaii conference a success! 🌟
We deeply appreciate and value your partnership.
Hope to see you all next year, in Maui August 3-7 ⭐️
Mahalo!! 🌺
@glomcon.org
We deeply appreciate and value your partnership.
Hope to see you all next year, in Maui August 3-7 ⭐️
Mahalo!! 🌺
@glomcon.org
September 29, 2025 at 7:42 PM
Everybody can reply
1 reposts
1 likes
Huge thank you to our incredible faculty, attendees, sponsors, and GlomCon instructors for making #GlomConHawaii conference a success! 🌟
We deeply appreciate and value your partnership.
Hope to see you all next year, in Maui August 3-7 ⭐️
Mahalo!! 🌺
We deeply appreciate and value your partnership.
Hope to see you all next year, in Maui August 3-7 ⭐️
Mahalo!! 🌺
September 29, 2025 at 7:40 PM
Everybody can reply
1 likes
I heard of the exercise stress test, the Persantine Cardiolite stress test but until today I was unaware of the Ritz Carlton Stress Test #GlomCon
September 28, 2025 at 5:40 PM
Everybody can reply
1 likes
Roven asked about how fast to update the guidelines. Sounds like he was on the writing panel. How can we keep up?
They are planning on shorter more frequent commentaries. Maybe yearly updates. #GlomCon
They are planning on shorter more frequent commentaries. Maybe yearly updates. #GlomCon
September 26, 2025 at 2:17 AM
Everybody can reply
3 likes
Fervenza has been asked about galactose deficient IgA1. He says he is going to be nice but then says he has nothing nice to say about KDIGO.
He says guidelines are always backward looking. No answer about Gd-IgA1 though
#GlomCon
He says guidelines are always backward looking. No answer about Gd-IgA1 though
#GlomCon
September 26, 2025 at 2:14 AM
Everybody can reply
1 reposts
4 likes
He wrote a 12 page letter criticizing the guidelines last year. He feels they are not timely. Database closed in August 2024.
He discloses that he is the editor of the GN section of UpToDate. He remarks that the editorial staff is much smaller than KDIGO. #GlomCon
He discloses that he is the editor of the GN section of UpToDate. He remarks that the editorial staff is much smaller than KDIGO. #GlomCon
September 26, 2025 at 2:10 AM
Everybody can reply
3 likes
September 26, 2025 at 2:03 AM
Everybody can reply
4 reposts
8 likes
1 saves
It wouldn't be an @edgarvlermamd.bsky.social lecture without a Spiderman ref #GlomCon
September 26, 2025 at 1:45 AM
Everybody can reply
2 reposts
7 likes
Outcomes for the rest of the basket should be coming soon-ish. I’m on the writing group but we haven’t met yet. #Glomcon
September 25, 2025 at 10:13 PM
Everybody can reply
3 likes
Results show significant reduction in proteinuria and stable GFR regardless of how effective the reduction of proteinuria (45% of patients achieved <500 mg/d of proteinuria) #GlomCon
September 25, 2025 at 10:06 PM
Everybody can reply
6 likes
1 saves
Next up Zigakibart in IgAN treated for 76 weeks.
Zigakibart is an April inhibitor (learned how to access the poster slides, so screen grabs rather than photos of the slides)
Title, methods, and table 1 demographics #GlomCon
Zigakibart is an April inhibitor (learned how to access the poster slides, so screen grabs rather than photos of the slides)
Title, methods, and table 1 demographics #GlomCon
September 25, 2025 at 10:04 PM
Everybody can reply
5 reposts
9 likes
2 saves
September 25, 2025 at 9:53 PM
Everybody can reply
3 likes
1 saves
Barratt then presented phase 2 data on atrasentan in IGAN on subgroups. This was an open label basket trial that looked at a number of diseases, but this is only data from IGAN. Outcome was proteinuria at 12 weeks #GlomCon
September 25, 2025 at 9:50 PM
Everybody can reply
1 reposts
5 likes
Jonathon Barrat up to discuss reduction in urinary biomarkers with sparsanten showing an impressive reduction in infalmmatory and fibrotic factors. Maybe endothelin antagonists are not just hemodynamic #GlomCon
September 25, 2025 at 9:20 PM
Everybody can reply
6 likes
1 saves
Abstract presentation
52 week results from VALIANT of pegcetacoplan for C3G
68% reductionin protein at 26 weeks
stabilization of GFR (+6.3 ml/min vs placebo)
72% reduction in nephrotic range proteinuria
#GlomCon
52 week results from VALIANT of pegcetacoplan for C3G
68% reductionin protein at 26 weeks
stabilization of GFR (+6.3 ml/min vs placebo)
72% reduction in nephrotic range proteinuria
#GlomCon
September 25, 2025 at 8:55 PM
Everybody can reply
5 likes